Heart failure is usually not the result of a single specific cause. heart failure can result from a combination of causes, including coronary artery disease and cardiomyopathy.\n
There is no single treatment for heart failure. Treatment may range from medications to surgery, pacemakers, or transcutaneous/artificial left/right ventricular assist pumps, among other options. Some of the treatments (e.g. pacemakers or ventricular assist pump) can be combined using a device called a dual-chamber pacemaker. Some heart failure treatment guidelines recommend combining medication, device therapy, exercise, or surgery in some cases.
Heart failure is a medical condition that can be caused by an interruption in the normal physiological functioning of the heart, most commonly by the heart muscle not pumping efficiently.\n
Heart failure patients may have reduced survival rates as compared to a comparison group, but these differences are similar to those that exist within the general population. There is no difference in survival rates between patients receiving treatment or those left untreated.
Only 1 in 28,000 new Americans suffers from acute heart failure each year. But this number can rise dramatically in the next year and may reach 2 in 3,000 every year. Even a very mild grade of heart failure in a person with no prior cardiovascular disease raises the prospect of high-risk morbidity and mortality.
There are many different signs and symptoms of heart failure. Some of the common ones are shortness of breath or chest pain, or palpitations.\n\n- Advanced Symptoms"
"Eugenia baehrii\n\nEugenia baehrii is a species of plant in the family Myrtaceae. It is a native of New Caledonia.
Semaglutide is a GLP-1 (glucagon-like peptide 1) analog for once-weekly subcutaneous injection without food intake. When administered once-weekly, semaglutide is efficacious and well-tolerated in adults with the long-term glucagon analogs.
Semaglutide is generally well-tolerated in people with type 2 diabetes. Most adverse events were mild to moderate and were not serious. There was no evidence of accelerated fracture healing after semaglutide therapy and no evidence that semaglutide increased the risk of cancer or cardiovascular events. Clinical trial registration NCT01811478.
Given our inability to predict which patients respond to treatments or benefit from treatments, it comes as no surprise that patient opinion and their own perception of what treatment is best for them are the most important predictors of treatment decision-making. For individuals who have left ventricular dysfunction, their view of the benefit of particular drugs is a much more important consideration than what current evidence suggests as to the efficacy of the drug. Furthermore, for many individuals the only evidence of efficacy comes from patient data that has been pooled from several clinical trials. This suggests that individualised treatment, based on the individual patient's view of benefit and the efficacy of treatment will be the only way forward.
Results from a recent paper is the first description of a semaglutide trial in a population with Type 2 diabetes that was mainly supported using exogenous insulin to control blood glucose. This represents a significant extension of the clinical efficacy of semaglutide to include a subset of patients with Type 2 diabetes for whom other treatments are inadequate. A similar trend was noted with body weight reductions. A larger trial of this medication will prove important as it may support the use of semaglutide over injectable and oral insulin therapy for a patient population that has few options.
SGLT2 is a promising therapeutic agent for hyperglycemia with or without diabetes, for which new therapies are sorely needed. Its potential role for treatment of type 2 diabetes is particularly promising given the increasing prevalence of obesity and associated insulin resistance.
At present, we have little knowledge about the process by which heart failure develops and the mechanisms of the disease and as we progress our understanding of these things will likely influence both research as well as clinical practice to better the current management of the disease.